New Mexico Honey Wound Treatment Research Study
Overview
- Phase
- Phase 2
- Sponsor
- R. Stephen Rankin, M.D.
- Enrollment
- 60
- Locations
- 1
- Primary Endpoint
- Size of lesion at day 7
Overview
Brief Summary
In a time of emerging bacteria that are resistant to antibiotics, honey offers an alternative that has potential to reduce the heavy reliance on pharmaceutical antibiotics. We will be evaluating the effectiveness of a locally produced New Mexico Honey against the standard of care Bactrim antibiotic on Community Acquired MRSA.
Detailed Description
Locally grown New Mexico Honey will be utilized on abscess wounds of the trunk and extremities vs routine (Bactrim) antibiotic care to determine if NM Honey is effective treatment for Community Acquired MRSA 6 cm abscesses.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 16 Years to 75 Years (Child, Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Patients 16 years of age or older
- •Abscess less than or equal to 6 cm in diameter on the extremity or trunk requiring incision and drainage
- •Patient willing to try honey prepared dressing
- •Patient able to return to office each day for 7 days for evaluation
Exclusion Criteria
- •Under the age of 16
- •Abscess of face, scalp or genitals
- •Diagnosed as a diabetic
- •Allergic to bee pollen, honey or sulfa antibiotics
- •Diagnosed with peripheral vascular disease
- •Patient acknowledgement of current drug or alcohol abuse
Arms & Interventions
NM Regional Honey
15 ml of NM Honey applied directly to wound
Intervention: New Mexico Honey (Drug)
NM Regional Honey
15 ml of NM Honey applied directly to wound
Intervention: Bactrim DS (Drug)
Bactrim DS
Standard of Care Oral Antibiotic
Intervention: New Mexico Honey (Drug)
Bactrim DS
Standard of Care Oral Antibiotic
Intervention: Bactrim DS (Drug)
Outcomes
Primary Outcomes
Size of lesion at day 7
Time Frame: 7 days
Increase in size will determine failure; Decrease in size will determine success
Secondary Outcomes
No secondary outcomes reported
Investigators
R. Stephen Rankin, M.D.
Primary Investigator
Rankin, R. Stephen, M.D.